Compare F5 Inc (FFIV) vs Pfizer Inc (PFE) Price & Performance

F5 (FFIV) trades at $400.23, down 3.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, and raised its fiscal outlook, driven by 19% product revenue growth. Fundamentals show robust profitability with a net income margin of 21.95% and consistent revenue growth, though valuation ratios like a P/E of 31.89 appear elevated. Analyst sentiment is mixed with a 40% buy rating.

The outlook is cautiously optimistic given earnings momentum and raised guidance, but risks include high valuation and competitive pressures. The consensus price target of $430.43 suggests modest upside potential from current levels, contingent on sustained execution in application security and hybrid cloud demand.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.